On April 10 local time, Norwegian Radio and television (NRK) reported that the Norwegian study pointed out that there was a link between the AstraZeneca vaccine and thrombosis, but researchers still did not know which substances in the vaccine would trigger this side effect. The researchers studied five Norwegian patients, 32 to 54 years old, who developed abnormal blood clots and low platelet counts within 10 days of being injected the AstraZeneca vaccine, and three patients died.
The study was published in the New England Journal of Medicine on the 9th. The results showed that the common point of the five patients is that the antibody levels of platelet factor 4 (PF4) and polyanion compound are very high. These types of antibodies can activate and lead to low platelet count, which is called vaccine inducing immune thrombocytopenia (Vitt) by researchers.
“It’s a drug side effect situation in which antibodies are formed against heparin based drugs,” said Ingvild Srvoll, chief physician of the UNN team at Tromso. However, these patients were not treated with heparin. When we looked at the literature, we never described this antibody after vaccination
Medson, the medical director of the Norwegian drug administration, said it was not known what triggered the side effects, so the study was very important and provided a basis for further research.
Madson said the study will affect the decision of the Norwegian Institute of public health (FHI) whether to re vaccinate AstraZeneca.It is reported that Norway stopped the vaccination of the new AstraZeneca vaccine in early March, and the Norwegian Institute of public health will announce whether to re vaccinate the vaccine on April 15.